Benzhydrocodone (INN) (contracted from benzoate-hydrocodone) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule. It is designed to be an opioid analgesic with a low chance of recreational use.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - Benzhydrocodone (INN) (contracted from benzoate-hydrocodone) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule. It is designed to be an opioid analgesic with a low chance of recreational use. (en)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
c
| |
CAS number
| |
ChEMBL
| |
ChemSpiderID
| |
DrugBank
| |
H
| |
image
| - Benzhydrocodone molecule ball.png (en)
|
IUPAC name
| |
KEGG
| |
n
| |
O
| |
PubChem
| |
routes of administration
| |
SMILES
| - CN1CC[C@]23c4c5cccOC (en)
|
StdInChI
| |
StdInChIKey
| - VPMRSLWWUXNYRY-PJCFOSJUSA-N (en)
|
synonyms
| |
UNII
| |
has abstract
| - Benzhydrocodone (INN) (contracted from benzoate-hydrocodone) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule. It is designed to be an opioid analgesic with a low chance of recreational use. Created by Kempharm, Inc., a biopharmaceutical company in Coralville, Iowa, President and CEO, Travis Mickle, believes the molecular-based approach to abuse deterrent may be more effective than many formulation-based approaches. When approved, Apadaz received a labeling that highlighted all relevant aspects of the drug, including the lower abuse profile compared to traditional hydrocodone-acetaminophen. The labeling showed several items supporting a lower abuse profile than traditional hydrocodone-acetaminophen; namely, a lower Drug Liking in the first two hours after intranasal abuse (snorting), and the conversion of benzhydrocodone to hydrocodone in vitro being a "difficult process" -- with benzhydrocodone being a more difficult drug to abuse according to FDA Apadaz adcom documents. (en)
|
gold:hypernym
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
CAS number
| |
ChEMBL
| |
DrugBank
| |
FDA UNII code
| |
KEGG
| |
PubChem
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is foaf:primaryTopic
of | |